CTI BioPharma Corp. (CTIC) Bundle
A Brief History of CTI BioPharma Corp. (CTIC)
Establishment and Early Years
Establishment and Early Years
CTI BioPharma Corp. was founded in 2000, originally under the name Cell Therapeutics, Inc. The company was established to develop and commercialize innovative, targeted therapies for patients with cancer. The initial focus was on developing a novel, small-molecule drug known as pixantrone.
Initial Public Offerings
CTI BioPharma went public on the NASDAQ exchange in 2004. The IPO raised approximately $35 million at an initial price of $6 per share. This influx of capital was intended to support clinical development programs.
Development of Pixantrone
Pixantrone (trade name: Marqibo) was primarily developed as a treatment for non-Hodgkin lymphoma. In 2010, CTI BioPharma submitted a New Drug Application (NDA) to the FDA, which was subsequently rejected in 2011 due to concerns regarding its efficacy and safety profile.
Acquisition of Additional Assets
In 2014, CTI BioPharma acquired the rights to additional compounds, including the investigational drug pacritinib, which targets myelofibrosis. The acquisition was a pivotal moment, allowing the company to diversify its pipeline.
Public Offerings and Financial Growth
Throughout the years, CTI BioPharma completed several public offerings. Notably, in January 2015, the company raised $45 million through a public offering of common stock at a price of $1.85 per share.
Recent Developments: Pacritinib
In 2021, CTI BioPharma received FDA approval for pacritinib, which was indicated for patients with primary or secondary myelofibrosis. The approval marked a significant milestone for the company, facilitating the launch of a new therapeutic option. In the third quarter of 2022, pacritinib generated revenue of approximately $11.2 million.
Financial Performance
For the fiscal year 2022, CTI BioPharma reported total revenues of $20 million, up from $5.3 million in 2021. The net loss for 2022 was approximately $48 million, compared to $37.5 million in 2021.
Stock Performance
As of October 2023, the stock price of CTI BioPharma (CTIC) was approximately $2.45 per share, reflecting a market capitalization of around $240 million.
Current Pipeline
CTI BioPharma's pipeline includes:
- Pacritinib for myelofibrosis
- Additional compounds targeting hematologic malignancies
- Ongoing clinical trials to expand treatment indications
| Year | Revenue ($ Million) | Net Loss ($ Million) | Stock Price ($) |
|---|---|---|---|
| 2020 | 5.3 | 37.5 | 1.85 |
| 2021 | 20 | 48 | 2.45 |
| 2022 | 20 | 48 | 2.45 |
| 2023 (Oct) | N/A | N/A | 2.45 |
Future Outlook
CTI BioPharma aims to expand its market presence and explore new therapies. The ongoing development of its pipeline is projected to enhance the company's growth trajectory and shareholder value in the coming years.
A Who Owns CTI BioPharma Corp. (CTIC)
Corporate Overview
Corporate Overview
CTI BioPharma Corp. is a biopharmaceutical company focused on developing therapies for cancer patients. As of October 2023, it operates primarily in the development of treatments for hematologic malignancies.
Shareholder Composition
The ownership structure of CTI BioPharma is characterized by institutional investors, retail investors, and company insiders. The following table details the significant shareholders and their respective ownership percentages:
| Shareholder Type | Shareholder Name | Ownership Percentage | Number of Shares Owned |
|---|---|---|---|
| Institutional Investor | The Vanguard Group, Inc. | 12.5% | 3,250,000 |
| Institutional Investor | BlackRock, Inc. | 10.2% | 2,640,000 |
| Institutional Investor | State Street Corporation | 8.7% | 2,200,000 |
| Insider | James A. Bianco, M.D. (CEO) | 5.0% | 1,300,000 |
| Retail Investor | Public Float | 63.6% | 16,800,000 |
Market Capitalization
As of October 2023, CTI BioPharma Corp. has a reported market capitalization of approximately $260 million.
Stock Performance
The stock performance of CTI BioPharma has shown volatility over the past year. Key financial metrics include:
| Metric | Value |
|---|---|
| Current Share Price | $3.25 |
| 52-Week High | $4.50 |
| 52-Week Low | $2.10 |
| Year-to-Date Return | -5.6% |
Recent Developments
In 2023, CTI BioPharma announced significant advancements in its clinical trials. The company reported:
- Phase 3 trial results for its lead product candidate, pacritinib.
- Partnership agreements with major biotech firms for collaborative research.
- An increase in research and development expenditures by 20% compared to the previous fiscal year.
Future Outlook
Analysts project potential growth in CTI BioPharma's valuation contingent upon successful trial results and market approvals in the next 12-18 months.
Conclusion of Ownership Analysis
CTI BioPharma's ownership landscape reflects a blend of institutional investment and public trading, while the company continues to focus on enhancing its market position through innovative therapies.
CTI BioPharma Corp. (CTIC) Mission Statement
Mission Statement Overview
CTI BioPharma Corp. is committed to developing and commercializing innovative therapies to treat cancer and blood-related diseases. The company aims to improve patient outcomes through targeted treatment solutions.
Goals and Objectives
- To develop therapies that address unmet medical needs in hematology.
- To enhance the quality of life for patients undergoing treatment.
- To conduct clinical trials that ensure safety and efficacy.
- To achieve regulatory approval for new therapies in a timely manner.
Financial Overview
As of Q2 2023, CTI BioPharma reported a total revenue of $11.1 million. The company has seen a significant increase in revenue compared to $2.1 million in Q2 2022.
Research and Development Investment
CTI BioPharma has allocated approximately $20 million for R&D in 2023, focusing on developing novel therapies for hematological malignancies.
| Year | Total Revenue ($ million) | R&D Expenses ($ million) | Net Loss ($ million) |
|---|---|---|---|
| 2021 | 5.3 | 17.8 | (29.1) |
| 2022 | 9.2 | 19.4 | (30.5) |
| 2023 (Q2) | 11.1 | 20.0 | (15.0, projected) |
Strategic Partnerships
CTI BioPharma has formed strategic partnerships to enhance its development capabilities. Key collaborations include:
- Partnered with Seattle Genetics for the development of antibody-drug conjugates.
- Collaboration with leading academic institutions for research purposes.
- Joint ventures aimed at expanding market reach in Asia and Europe.
Pipeline Overview
CTI BioPharma's pipeline focuses on innovative therapies, with four main candidates in various stages:
- Pacritinib: Undergoing Phase 3 trials for myelofibrosis.
- CTI-1601: In Phase 1 trials for sickle cell disease.
- CTI-105: Investigational therapy for acute myeloid leukemia.
- CTI-124: Targeting patients with various myeloid malignancies.
Market Position
As of 2023, CTI BioPharma holds a market capitalization of approximately $112 million, reflecting investor confidence in the company's growth potential and innovative pipeline.
Regulatory Milestones
CTI BioPharma has achieved significant regulatory milestones, including:
- FDA approval for Pacritinib in February 2022.
- Fast Track Designation for CTI-1601 in March 2023.
- Orphan Drug Designation for CTI-105 in May 2023.
Conclusion
CTI BioPharma continues to focus on innovation and addressing the critical needs of patients with hematological diseases, maintaining a strong ethical commitment to its mission.
How CTI BioPharma Corp. (CTIC) Works
Overview of CTI BioPharma Corp.
CTI BioPharma Corp. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for blood-related cancers. It primarily targets conditions such as acute myeloid leukemia (AML) and myelofibrosis.
Key Products
CTI BioPharma's lead product candidate is pacritinib, which has gained attention for its potential in treating myelofibrosis.
| Product | Indication | Status | Year of FDA Approval | Market Potential ($ billion) |
|---|---|---|---|---|
| Pacritinib | Myelofibrosis | Approved | 2022 | $2.7 |
Financial Performance
The company has shown varying financial metrics over recent years. As of Q3 2023, here are the key statistics:
| Financial Metric | Q3 2022 | Q3 2023 | Change (%) |
|---|---|---|---|
| Revenue ($ million) | $5.5 | $15.2 | 174.55 |
| Net Income ($ million) | ($12.3) | ($5.8) | 53.66 |
| Total Assets ($ million) | $50.1 | $73.0 | 45.69 |
Research and Development Strategy
CTI BioPharma allocates a significant portion of its budget towards R&D.
- R&D Expense in 2022: $21.5 million
- Projected R&D Expense in 2023: $28.0 million
- Clinical Trials: Over 5 ongoing major trials
Market Presence and Collaborations
CTI BioPharma has established collaborations to enhance its market presence:
- Partnership with Sarepta Therapeutics for co-development.
- Distribution agreements in Europe and Asia.
Stock Performance
As of October 2023, CTI BioPharma's stock performance showed notable metrics:
| Metric | Value |
|---|---|
| Current Stock Price | $4.10 |
| Market Capitalization ($ billion) | $0.66 |
| 52-Week Range | $2.50 - $5.00 |
| P/E Ratio | N/A (negative earnings) |
Regulatory Overview
CTI BioPharma adheres to stringent regulatory frameworks in drug development, including:
- FDA approval processes
- Compliance with EMA regulations
- Ongoing clinical trial registries
How CTI BioPharma Corp. (CTIC) Makes Money
Revenue Streams
Revenue Streams
CTI BioPharma Corp. primarily generates revenue through the commercialization of its products and collaborations with other pharmaceutical companies. As of the latest financial statements, the following are the main revenue components:
- Product Sales: Revenue from the sale of the product Pixuvri (pixantrone) and other drugs.
- Collaborative Agreements: Income from partnerships with other biotech and pharmaceutical companies.
- Licensing Revenue: Fees and milestones from licensing agreements.
Product Sales
In 2022, CTI BioPharma reported product sales of approximately $18 million. The primary product contributing to these sales is Pixuvri, which was approved for marketing in the European Union and is indicated for certain types of blood cancers.
Collaborative Agreements
CTI BioPharma has entered into multiple collaborative agreements that enhance its financial standing. In 2022, revenue from collaborative agreements reached $10 million, primarily derived from partnerships aimed at clinical developments and joint marketing efforts.
Licensing Revenue
In 2022, CTI BioPharma generated approximately $5 million in licensing revenue from various agreements, which included upfront payments and milestone achievements as part of long-term licensing contracts.
| Revenue Source | 2022 Amount |
|---|---|
| Product Sales | $18 million |
| Collaborative Agreements | $10 million |
| Licensing Revenue | $5 million |
Research and Development (R&D)
CTI BioPharma invests heavily in R&D to develop innovative therapies. In 2022, the company reported R&D expenses amounting to approximately $22 million, focusing on advancing its pipeline therapies, particularly for hematological malignancies.
Key Product Pipeline
CTI BioPharma's pipeline includes several investigational drugs that are designed to treat various forms of cancer. The success of these drugs in clinical trials is essential for future revenue generation. The estimated market potential for these products is projected to be in the range of $1 billion over the next decade if successful.
Market Strategies
The company's market strategies include:
- Focus on Niche Markets: Targeting specific blood cancers where competition is limited.
- Strategic Partnerships: Collaborating with established pharmaceutical companies for distribution and marketing.
- Investment in Clinical Trials: Prioritizing R&D to enhance product efficacy and obtain regulatory approvals.
Financial Performance
For the fiscal year ending December 31, 2022, CTI BioPharma reported total revenues of $33 million, a notable increase from the previous year's revenue of $28 million. However, the net loss for the same period was approximately $27 million, reflecting ongoing investments in R&D and expansion efforts.
| Financial Metric | 2022 Amount | 2021 Amount |
|---|---|---|
| Total Revenues | $33 million | $28 million |
| Net Loss | $27 million | $24 million |
| R&D Expenses | $22 million | $20 million |
Conclusion
CTI BioPharma Corp. continues to explore diverse revenue streams through product sales, collaborative agreements, and licensing, while emphasizing R&D investments to secure its future in the biopharmaceutical landscape.
CTI BioPharma Corp. (CTIC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support